scholarly journals EPIDEMIOLOGICAL AND CLINICAL CHARACTERISTICS OF 2019 NOVEL CORONA VIRUS: A REVIEW

2021 ◽  
pp. 1-6
Author(s):  
T SAI LAKSHMI SRIKALA ◽  
T PRAVEEN KUMAR
Keyword(s):  
Middle East ◽  
Clinical Characteristics ◽  
Treatment Strategies ◽  
Dromedary Camels ◽  
Wuhan City ◽  
The World ◽  
Novel Coronavirus ◽  
Country Office ◽  
Better Than ◽  
Living Being

Middle East Respiratory Syndrome (MERS), having a high demise rate, which radiate from the Middle East. Novel Coronavirus is the causative living being for MERS and (2019-nCoV) was recognized infection by Chinese experts on January 7. On December 31, 2019, the WHO China Country Office was educated regarding instances of pneumonia of obscure etiologic (obscure reason) identified in Wuhan City, Hubei Province of China. Besides, MERS-CoV first found in dromedary camels and in bats, people. Proof recommends that animals are acting as host for MERS-CoV and transmitting the malady to people. Till the finish of November 2019, an aggregate of 2494 lab instances of MERS, were recorded which incorporates 858 deaths around the world. At present, no drug or immunization is accessible for MERS. As we knew that prevention is better than cure, taking precautions before attacking of the disease is the best way of preventing disease. In this study, we discussed about the pathological aspects, treatment strategies, and precautions of the disease.

scholarly journals COVID-19 Diagnosis, Treatments and Prevention: A Review

2020 ◽  
pp. 17-34
Author(s):  
Soumik Chatterjee ◽  
Sabyasachi Chatterjee
Keyword(s):  
Immune System ◽  
Respiratory Tract ◽  
World Health Organization ◽  
Clinical Characteristics ◽  
Treatment Strategies ◽  
World Health ◽  
Upper Respiratory Tract ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization

Novel Coronavirus are very harmful virus. This viruses have positive single stranded RNA genome and enveloped which is called nucleocapsid. The family of this virus is Coronaviridae. This virus originated from species of avian and mammalian. This virus effect on upper respiratory tract in humans. Many species of these novel coronaviruses (HCoVs) are named as HCoV-HKU1, HCoV-NL63. Predominant species of this virus is Middle East respiratory syndrome (MERS-CoV) across the world.  In both adults and childrens HCoV-HKU1 sp. is causes for chronic pulmonary disease and HCoV-NL63 species causes for upper and lower respiratory tract disease. Most recent species of this virus is MERS-CoV. This species caused for acute pneumonia and occasional renal failure. The new strain of novel Coronavirus is SARS-CoV-2. This strain causes for the Coronavirus Disease 2019 (COVID-19). This disease named by the World Health Organization. Now world fighting against COVID-19 and according to the recent statistics report of world about the COVID-19 cases approx 22.6M confirmed cases and 792K death cases appeared and recovered 14.5M. COVID-19 disease starts to spread from December 2019 from china. Covid-19 disease is emerged in Wuhan seafood market at Wuhan of South China and then rapidly spread throughout the world. The corona virus outbreak has been declared a public health emergency of International concern by World Health Organization (WHO). In this article we summarize the current clinical characteristics of coronavirus and diagnosis, treatments and prevention of COVID-19 disease. In this review article, we analyze data from various Research Reports like WHO guidelines and other articles. It is very important to the readers that new data of COVID-19 updating nearly every hour of day regarding clinical characteristics, diagnosis, treatment strategies, and outcomes COVID-19 disease. The degree of COVID-19 disease varying throughout the world. COVID-19 affected patient shows various symptoms like fever, cough, sore throat, breathlessness, fatigue, and malaise among others. The COVID-19 disease is being treated through general treatment like symptomatic treatment, by using antiviral drugs, oxygen therapy and by the immune system. There is no vaccine or therapeutic strategies for deal with this disease yet. In this critical situation preventive measures must be require.  A very important issue in preventing viral infection is hand hygiene. There are other entities that people can boosting the immune system and help in infection prevention.

Evolution, Ayurveda, immunity, and preventive aspects for emerging infectious diseases such as COVID-19

2020 ◽  
Vol 11 (SPL1) ◽  
pp. 86-93
Author(s):  
Dhirajsingh Sumersingh Rajput
Keyword(s):  
Infectious Diseases ◽  
Continuous Process ◽  
Physiological Mechanism ◽  
Emerging Infectious Diseases ◽  
Personal Hygiene ◽  
Breathing Exercise ◽  
Theory Of Evolution ◽  
Novel Coronavirus ◽  
Better Than ◽  
Living Being

Evolution is continuous process of changes in structural and physiological mechanism in living being. Microbes/pathogens can evolve naturally or artificially and become resistant to various medicines. Novel coronavirus is such evolved pathogen of coronavirus group. Enough strong immunity is needed to prevent or survive from COVID-19 pandemic. Ayurveda provides ways for evolving physiological responses to built immunity. Present work is brief attempt to increase insight in this filed.Present review was done based on simple theory of evolution, recent updates regarding prevention of COVID-19, Ayurveda aspect toward infectious diseases and Ayurveda ways towards prevention of infectious diseases with special reference to COVID-19. Person with impaired immunity is more susceptible for COVID-19 and thus immunity is an important preventing factor. Ayurveda Rasayana (rejuvanation) herbs, Yoga exercises, Pranayama (special breathing exercise), daily regimens and personal hygiene guidelines can be helpful strategies in controlling the spread of COVID-19.The preventive aspects of pandemic situations are narrated in Ayurveda with enough details. These ways need to be scientifically explored and refined for precision. As prevention is always better than cure hence Ayurveda ways can be considered for future strategies to avoid pandemics such as COVID-19.  There is great need of research on Ayurveda medicines on COVID-19 like diseases.

Treatment Options in COVID-19: The Role of Bioavailable Antiviral Ribonucleoside Analog on NHC in vitro

2020 ◽  
Author(s):  
Lara Bittmann
Keyword(s):  
World Health Organization ◽  
Clinical Picture ◽  
Treatment Options ◽  
World Health ◽  
Wuhan City ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization

On December 31, 2019, WHO was informed of cases of pneumonia of unknown cause in Wuhan City, China. A novel coronavirus was identified as the cause by Chinese authorities on January 7, 2020 and was provisionally named "2019-nCoV". This new Coronavirus causes a clinical picture which has received now the name COVID-19. The virus has spread subsequently worldwide and was explained on the 11th of March, 2020 by the World Health Organization to the pandemic.

scholarly journals Does the novel coronavirus 2019 like heart more than the other family members of coronaviruses?

2020 ◽  
Vol 12 (2) ◽  
pp. 156-157
Author(s):  
Mohammad Mostafa Ansari Ramandi ◽  
Mohammadreza Baay ◽  
Nasim Naderi
Keyword(s):  
Middle East ◽  
Severe Acute Respiratory Syndrome ◽  
Family Members ◽  
Middle East Respiratory Syndrome ◽  
The Other ◽  
The Novel ◽  
The World ◽  
Future Challenges ◽  
Novel Coronavirus ◽  
Coronavirus Infections

The disaster due to the novel coronavirus disease 2019 (COVID-19) around the world has made investigators enthusiastic about working on different aspects of COVID-19. However, although the pandemic of COVID-19 has not yet ended, it seems that COVID-19 compared to the other coronavirus infections (the Middle East Respiratory Syndrome [MERS] and Severe Acute Respiratory Syndrome [SARS]) is more likely to target the heart. Comparing the previous presentations of the coronavirus family and the recent cardiovascular manifestations of COVID-19 can also help in predicting possible future challenges and taking measures to tackle these issues.

scholarly journals Early epidemiological assessment of the transmission potential and virulence of coronavirus disease 2019 (COVID-19) in Wuhan City: China, January-February, 2020

2020 ◽  
Author(s):  
Kenji Mizumoto ◽  
Katsushi Kagaya ◽  
Gerardo Chowell
Keyword(s):  
Basic Reproduction Number ◽  
Reproduction Number ◽  
Public Health Intervention ◽  
Ecological Modelling ◽  
The Novel ◽  
Wuhan City ◽  
Transmission Potential ◽  
The World ◽  
Novel Coronavirus ◽  
Epidemiological Parameters

AbstractBackgroundSince the first cluster of cases was identified in Wuhan City, China, in December, 2019, coronavirus disease 2019 (COVID-19) rapidly spread around the world. Despite the scarcity of publicly available data, scientists around the world have made strides in estimating the magnitude of the epidemic, the basic reproduction number, and transmission patterns. Accumulating evidence suggests that a substantial fraction of the infected individuals with the novel coronavirus show little if any symptoms, which highlights the need to reassess the transmission potential of this emerging disease. In this study, we derive estimates of the transmissibility and virulence of COVID-19 in Wuhan City, China, by reconstructing the underlying transmission dynamics using multiple data sources.MethodsWe employ statistical methods and publicly available epidemiological datasets to jointly derive estimates of transmissibility and severity associated with the novel coronavirus. For this purpose, the daily series of laboratory–confirmed COVID-19 cases and deaths in Wuhan City together with epidemiological data of Japanese repatriated from Wuhan City on board government–chartered flights were integrated into our analysis.ResultsOur posterior estimates of basic reproduction number (R) in Wuhan City, China in 2019–2020 reached values at 3.49 (95%CrI: 3.39–3.62) with a mean serial interval of 6.0 days, and the enhanced public health intervention after January 23rd in 2020 was associated with a significantly reduced R at 0.84 (95%CrI: 0.81–0.88), with the total number of infections (i.e. cumulative infections) estimated at 1906634 (95%CrI: 1373500–2651124) in Wuhan City, elevating the overall proportion of infected individuals to 19.1% (95%CrI: 13.5–26.6%). We also estimated the most recent crude infection fatality ratio (IFR) and time–delay adjusted IFR at 0.04% (95% CrI: 0.03%–0.06%) and 0.12% (95%CrI: 0.08–0.17%), respectively, estimates that are several orders of magnitude smaller than the crude CFR estimated at 4.06%ConclusionsWe have estimated key epidemiological parameters of the transmissibility and virulence of COVID-19 in Wuhan, China during January-February, 2020 using an ecological modelling approach. The power of this approach lies in the ability to infer epidemiological parameters with quantified uncertainty from partial observations collected by surveillance systems.

scholarly journals Molecular Docking Study of the Potential Relevance of the Natural Compounds Isoflavone and Myricetin to COVID-19

2021 ◽  
Vol 25 (3) ◽  
pp. 271-282
Author(s):  
Didik Priyandoko ◽  
◽  
Wahyu Widowati ◽  
Mawar Subangkit ◽  
Diana Jasaputra ◽  
...  
Keyword(s):  
Molecular Docking ◽  
Severe Acute Respiratory Syndrome ◽  
Active Sites ◽  
Docking Study ◽  
Binding Mode ◽  
Molecular Docking Study ◽  
Wuhan City ◽  
The World ◽  
Novel Coronavirus ◽  
Proteins Interactions

The 2019 novel coronavirus (2019-nCoV) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly from its origin in Wuhan City, Hubei Province, China, to the rest of the world. The efficacy of herbal treatment in the control of contagious disease was demonstrated during the 2003 outbreak of severe acute respiratory syndrome (SARS). Natural compound used for this study were isoflavone and myricetin. Molecular docking was performed to analyze binding mode of the compounds towards 12 proteins related to COVID-19. The prediction shows that isoflavone and myricetin have moderate probability of antiviral activity. All of the docked compounds occupied the active sites of the proteins related to COVID-19. Based on QSAR and molecular docking, interactions were predicted with 10 out of 12 potential COVID-19 proteins for myricetin and with 9 out of 12 proteins interactions for isoflavone. A potential disease alleviating action is suggested for isoflavone and myricetin in the context of COVID-19 infection.

COVID-19: Pakistan’s Preparedness and response

2021 ◽  
Vol 1 (4) ◽  
pp. e207
Author(s):  
Sahrish Khan ◽  
Atiq ur Rahman ◽  
Muhammad Imran
Keyword(s):  
Preventive Measures ◽  
Awareness Campaign ◽  
Wuhan City ◽  
The World ◽  
Novel Coronavirus

At the end of December 2019 in the Wuhan City of China, a novel coronavirus (Covid-19) outbreak has been proclaimed. Several cases have arisen in other cities of China. It spread simultaneously worldwide in 209 countries of Europe, Australia, America, Asia, and Pakistan. Mortality is high; millions of people have been affected while cases are rapidly increasing in the world. Different controlling strategies have been adopted for COVID-19. Pakistan took rigorous measures like the hospital, specific laboratories for testing, centres for quarantine, awareness campaign, Ehsaas Emergency Cash Programme and lockdown for controlling this virus. There is no antiviral and vaccine based treatment only preventive measures are taken.

scholarly journals The Covid-19 Between State of Emergency and Exception in Italy and Its Consequences on Human Rights

2020 ◽  
Vol 3 (2) ◽  
pp. 139
Author(s):  
Pina Sodano Omizzolo
Keyword(s):  
Human Rights ◽  
Middle East ◽  
Severe Acute Respiratory Syndrome ◽  
World Health Organization ◽  
Social Consequences ◽  
World Health ◽  
Wuhan City ◽  
State Of Emergency ◽  
The World ◽  
Health Organization

In mid-December 2019, several atypical cases of pneumonia were detected in hospitals in Wuhan City – Hubei Province – in Inner China. It turns out that the first patients had already fallen ill in early December or even mid-November. However, only on the last day of the year 2019, Chinese doctors were able to officially identify a new virus in a 41-year-old patient admitted 5 days earlier. The virus belongs to the class of “coronavirus”, the same to which the SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome) viruses belong. It is initially baptized 2019-nCov, or “new 2019 coronavirus”. In February, the official name assigned to the virus is Sars-COV-2 and the associated disease is named COVID-19. The outbreak took on considerable proportions in China and then spread to the rest of the world, leading the World Health Organization to declare the infection a “pandemic” on 11 March 2020. The containment strategies applied in the most affected countries have proved to be very different in effectiveness, to the point that the lethality of the virus appears very different from country to country. This difference in impact has led to different legal, economic and social consequences.

scholarly journals Another coronavirus, Another challenge

JMS SKIMS ◽  
2020 ◽  
Vol 23 (1) ◽  
pp. 1-2
Author(s):  
Rafi A Jan ◽  
Arif Rehman Sheikh
Keyword(s):  
Animal Species ◽  
Large Family ◽  
Animal Origin ◽  
Chinese Isolate ◽  
Wuhan City ◽  
Animal Reservoir ◽  
The World ◽  
Enteric Infections ◽  
The Many ◽  
Novel Coronavirus

The world is yet again challenged by the outbreak of a new coronavirus, named SARS-CoV-2; disease caused by this virus, now termed as COVID-19,was first reported in Wuhan City, Hubei Province China in the last week of December 2019. As of march 5, WHO reports a total of 80,430 cases of COVID-19 with 3013 deaths from China. The disease has been now reported in all the continents of the world except Antarctica –around 15,053 cases in 85 countries with 273 deaths. Although many cases have been reported in India, whether it going to touch this part of the country too, only time will tell.  It is very likely that by the time this editorial goes in print, the numbers would have changed significantly. It is because of this developing outbreak situation that has engulfed the entire world and has the potential to turn into a pandemic, I decided to focus on this new disease than to comment on one of the many well written papers in this issue of the journal. Understanding of this novel coronavirus, SARS-CoV-2, is evolving. This virus belongs to a large family of viruses known as coronaviridae family which are enveloped positive stranded RNA viruses causing respiratory and enteric infections affecting both animals and humans. The animal species infected by various coronaviruses include camels, cattle, cats and bats. Although very uncommon, coronaviruses of animal origin can infect humans and then spread from person to person, sometimes with devastating morbidity and mortality as is the case with MERS-CoV. The other two animal coronaviruses infecting people are SARS-CoV and SARS-CoV-2. All these three viruses are betacoronaviruses and have their origin in bats1. Sequences from SARS-CoV-2 generated from patients outside China are similar to the original Chinese isolate suggesting a likely single emergence of SARS-CoV-2 from an animal reservoir. In the coming months we expect to learn more about the evolution and other pathogenetic aspects of the disease caused by SARS-CoV-2

scholarly journals Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study

2020 ◽  
Author(s):  
Xudan Chen ◽  
Yuying Zhang ◽  
Baoyi Zhu ◽  
Jianwen Zeng ◽  
Wenxin Hong ◽  
...  
Keyword(s):  
Clinical Characteristics ◽  
Time Lag ◽  
Treatment Strategies ◽  
Antiviral Drugs ◽  
Viral Rna ◽  
The Novel ◽  
Illness Onset ◽  
Treatment Regimens ◽  
Global Pandemic ◽  
Novel Coronavirus

AbstractBackgroundThe novel coronavirus disease 2019 (COVID-19) characterized by respiratory symptoms has become a global pandemic although factors influencing viral RNA clearance remained unclear to inform optimal isolation period and treatment strategies.MethodsIn this retrospective study, we included patients with confirmed COVID-19 admitted to Guangzhou Eighth People’s Hospital from 20th January 2020 to 15th March 2020. The associations of clinical characteristics and treatment regimens on time to viral RNA clearance were analyzed.ResultsWe examined 284 consecutive COVID-19 cases, accounting for 82% of confirmed cases in Guangzhou during this period. At the time of reporting (20th March 2020), 276 (97.2%) had recovered and were discharged from hospital with a median hospital stay of 18 days (interquartile range [IQR]:13-24). Overall, 280 patients achieved viral RNA clearance with a median length of 12 days (IQR: 8-16) after onset of illness. Amongst them, 66.1% had viral RNA cleared within 14 days, and 89.3% within 21 days. Older age, severity of disease, time lag from illness onset to hospital admission, high body temperature, and corticosteroid use were associated with delayed clearance of viral RNA. None of the antiviral regimens (chloroquine, oseltamivir, arbidol, and lopinavir/ritonavir) improved viral RNA clearance. The use of lopinavir/ritonavir was associated with delayed clearance of viral RNA after adjusting for confounders.ConclusionIn patients with COVID-19, isolation for a minimum of 21 days after onset of illness may be warranted, while the use of antiviral drugs does not enhance viral RNA clearance.Brief SummaryViral RNA was cleared in 89% of the COVID-19 patients within 21 days after illness onset. The use of antiviral drugs (chloroquine, oseltamivir, arbidol, and lopinavir/ritonavir) did not shorten viral RNA clearance, especially in non-serious cases.

Sign in / Sign up

Export Citation Format

Share Document